Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02642016 | A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors | PHASE1 | COMPLETED | 28 | — | — | Dec 1, 2015 | Jun 4, 2019 | Jun 12, 2019 | 4 | United States |
| Arm | Type | Description |
|---|---|---|
| CDX-0158 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CDX-0158 (formerly known as KTN-0158) | BIOLOGICAL | Single agent CDX-0158 until unacceptable toxicity or progressive disease |
Inclusion Criteria: 1. Written informed consent and any locally required authorization (eg, HIPAA) obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations. 2. Metastatic or unresectable cancer that expresses KIT as document...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |